---
title: "Changchun High-Tech Industry Unit Gets China Clinical Trial Nod for Arthritis Injection"
date: "2025-02-11 12:05:05"
summary: "China's medical products administrator approved Changchun High-Tech Industry subsidiary Changchun Jinsai Pharmaceutical's clinical trial for its GenSci120 humanized anti-PD-1 monoclonal antibody injection. The drug kills pathogenic T cells and has the potential to treat autoimmune conditions. It is indicated for rheumatoid arthritis, according to a Tuesday filing with the Shenzhen..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

China's medical products administrator approved Changchun High-Tech Industry subsidiary Changchun Jinsai Pharmaceutical's clinical trial for its GenSci120 humanized anti-PD-1 monoclonal antibody injection.

The drug kills pathogenic T cells and has the potential to treat autoimmune conditions. It is indicated for rheumatoid arthritis, according to a Tuesday filing with the Shenzhen Stock Exchange.

The injection obtained clinical trial approval for adult systemic lupus erythematosus, adult primary Sj√∂gren's syndrome, and inflammatory bowel disease, the filing said.

Shares fell 2% during Tuesday's late morning trading.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465995:0/)
